Evidence map›Paper›PMID 25511521›Full record

ArticleBrain imaging and behavior2015

Anterior cingulate dopamine turnover and behavior change in Parkinson's disease.

Catherine L Gallagher, Brian Bell, Matthew Palotti, Jen Oh, Bradley T Christian, Ozioma Okonkwo, Jitka Sojkova, Laura Buyan-Dent, Robert J Nickles, Sandra J Harding and 3 more

Abstract read
In one paragraph

Article in Brain imaging and behavior, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Neurophysiological Biomarkers of Parkinson's Disease.Journal of Parkinson's disease · 2020
    Article
  8. Physiological Whole-Brain Distribution of [Molecular imaging and biology · 2019
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Catherine L GallagherWilliam S. Middleton Veterans Hospital, Madison, WI, USA. gallagher@neurology.wisc.edu.
Brian BellDepartment of Neurology, University of Wisconsin School of Medicine and Public Health, 7211 MFCB, 1685 Highland Ave., Madison, WI, 53705-2281, USA.
Matthew PalottiWilliam S. Middleton Veterans Hospital, Madison, WI, USA.
Jen OhAlzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Bradley T ChristianUniversity of Wisconsin Department of Medical Physics, Madison, WI, USA.
Ozioma OkonkwoAlzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Jitka SojkovaWilliam S. Middleton Veterans Hospital, Madison, WI, USA.
Laura Buyan-DentDepartment of Neurology, University of Wisconsin School of Medicine and Public Health, 7211 MFCB, 1685 Highland Ave., Madison, WI, 53705-2281, USA.
Robert J NicklesUniversity of Wisconsin Department of Medical Physics, Madison, WI, USA.
Sandra J HardingAlzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Charles K StoneDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Sterling C JohnsonWilliam S. Middleton Veterans Hospital, Madison, WI, USA.
James E HoldenUniversity of Wisconsin Department of Medical Physics, Madison, WI, USA.
University of Wisconsin–Madison · USWilliam S. Middleton Memorial Veterans Hospital · US

Funding

Institutional Clinical and Translational Science AwardUL1TR000427 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$32.2M
INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI JOHNSON, JEFFREY A · 2009 to 2018
$16.2M
CSRD VA I01 CX000555NCATS NIH HHS UL1 TR000427NCRR NIH HHS 1UL1RR025011NCRR NIH HHS UL1 RR025011NIA NIH HHS P50 AG033514
6 · The paper itself

Abstract

Subtle cognitive and behavioral changes are common in early Parkinson's disease. The cause of these symptoms is probably multifactorial but may in part be related to extra-striatal dopamine levels. 6-[(18) F]-Fluoro-L-dopa (FDOPA) positron emission tomography has been widely used to quantify dopamine metabolism in the brain; the most frequently measured kinetic parameter is the tissue uptake rate constant, Ki. However, estimates of dopamine turnover, which also account for the small rate of FDOPA loss from areas of specific trapping, may be more sensitive than Ki for early disease-related changes in dopamine biosynthesis. The purpose of the present study was to compare effective distribution volume ratio (eDVR), a metric for dopamine turnover, to cognitive and behavioral measures in Parkinson's patients. We chose to focus the investigation on anterior cingulate cortex, which shows highest FDOPA uptake within frontal regions and has known roles in executive function. Fifteen non-demented early-stage PD patients were pretreated with carbidopa and tolcapone, a central catechol-O-methyl transferase (COMT) inhibitor, and then underwent extended imaging with FDOPA PET. Anterior cingulate eDVR was compared with composite scores for language, memory, and executive function measured by neuropsychological testing, and behavior change measured using two informant-based questionnaires, the Cambridge Behavioral Inventory and the Behavior Rating Inventory of Executive Function-Adult Version. Lower mean eDVR (thus higher dopamine turnover) in anterior cingulate cortex was related to lower (more impaired) behavior scores. We conclude that subtle changes in anterior cingulate dopamine metabolism may contribute to dysexecutive behaviors in Parkinson's disease.

Indexed as

AdultAgedAged, 80 and overAntiparkinson AgentsBenzophenonesCarbidopaCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsDopamineFemaleGyrus CinguliHumansMaleMiddle AgedNeuropsychological TestsNitrophenols6-fluorodopamineAntiparkinson AgentsBenzophenonesCarbidopaCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsCOMT protein, humanDopamineNitrophenolsRadiopharmaceuticalsTolcaponeAdultAgedBrain mappingCerebral cortex/metabolism/radionuclide imagingDihydroxyphenylalanine/*analogs & derivatives/drug effects/pharmacokineticsDopamine agents/*diagnostic use/pharmacokineticsHumansParkinson disease/*physiopathology/*radionuclide imagingPositron emission tomographyResearch support/U.S. Gov’t/P.H.S.

Identifiers

PMID25511521
PMCPMC4469641
OpenAlexW2052070232

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.